menu
    • menu

    Company profile for TWi Pharmaceuticals

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    REF. STANDARDS & IMPURITIES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    TWi Pharmaceuticals, Inc. (TWi) is a technology-based special pharmaceutical company focusing on the development and commercialization of "High Barrier Generics" drugs primarily for United States. Unlike the common generic drugs, developing high barrier generic drugs require a full array of expertise, including advanced scientific research, process development, patent analysis, regulatory compliances, and market and competitio...
    TWi Pharmaceuticals, Inc. (TWi) is a technology-based special pharmaceutical company focusing on the development and commercialization of "High Barrier Generics" drugs primarily for United States. Unlike the common generic drugs, developing high barrier generic drugs require a full array of expertise, including advanced scientific research, process development, patent analysis, regulatory compliances, and market and competition analysis. TWi focuses on the development of the following two categories of high barrier generic drugs.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    TWi PharmaceuticalsTaiwan Flag
    Country
    Country
    Taiwan
    Address
    Address
    4F, No. 41, Lane 221, Kang Chien Rd., Nei Hu Dist. Taipei 114
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.twipharma.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    CVS Sues Takeda Over 'Pay-For-Delay' Scheme
    CVS Sues Takeda Over 'Pay-For-Delay' Scheme

    10 Sep 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/takeda-faces-another-pay-delay-antitrust-lawsuit-one-cvs-over-heartburn-drug-dexilant

    FIERCE PHARMA
    10 Sep 2025
    Share Share
    Strides Pharma subsidiary receives USFDA approval for 60 mg Fluoxetine tablets
    Strides Pharma subsidiary receives USFDA approval for 60 mg Fluoxetine tablets

    18 Sep 2024

    // EXPRESSPHARMA

    https://www.expresspharma.in/strides-pharma-subsidiary-receives-usfda-approval-for-60-mg-fluoxetine-tablets/

    EXPRESSPHARMA
    18 Sep 2024
    Share Share
    TWi Pharma's Generic Dicyclomine Hydrochloride Receives Approval in the U.S.
    TWi Pharma's Generic Dicyclomine Hydrochloride Receives Approval in the U.S.

    01 Jun 2023

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216782

    FDA
    01 Jun 2023
    Share Share
    TWi's Generic Dicyclomine Hydrochloride Receives Approval in the U.S.
    TWi's Generic Dicyclomine Hydrochloride Receives Approval in the U.S.

    27 Dec 2022

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217054

    FDA
    27 Dec 2022
    Share Share
    TWi's Generic Dexlansoprazole Receives Approval in the U.S.
    TWi's Generic Dexlansoprazole Receives Approval in the U.S.

    16 Sep 2022

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202666

    FDA
    16 Sep 2022
    Share Share
    Bora expands its CDMO capabilities, buying TWi Pharma
    Bora expands its CDMO capabilities, buying TWi Pharma

    13 Sep 2022

    // PRESS RELEASE

    https://bora-corp.com/bora-expands-its-cdmo-capabilities-as-it-makes-landmark-acquisition-of-twi-pharmaceuticals/

    PRESS RELEASE
    13 Sep 2022
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search